Synlogic's Net Loss Widens Amid Restructuring, Cash Holds Steady

TL;DR

**SYBX is a zombie biotech with no revenue and one employee, betting it all on a sale; avoid unless you love extreme speculation.**

AI Summary

SYNLOGIC, INC. (SYBX) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $2.301 million, compared to a net loss of $0.117 million for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $2.513 million, a substantial improvement from the $22.645 million loss in the prior year, primarily due to reduced operating expenses. Revenue remained at $0 for both the three and nine months ended September 30, 2025, down from $8 thousand in the nine months ended September 30, 2024. Research and development expenses plummeted to $8 thousand for the three months and $16 thousand for the nine months ended September 30, 2025, a drastic reduction from $713 thousand and $9.164 million, respectively, in 2024, following a corporate restructuring in February 2024 that reduced the workforce to one full-time employee. General and administrative expenses also decreased to $818 thousand for the quarter and $2.454 million for the nine months, down from $1.165 million and $5.228 million in the corresponding 2024 periods. The company's cash and cash equivalents stood at $15.591 million as of September 30, 2025, down from $18.860 million at December 31, 2024, but management believes this is sufficient to fund operations for at least the next 12 months. A significant change in the fair value of purchase warrant liability resulted in an expense of $1.485 million for the quarter, contrasting with a $376 thousand income in the prior year.

Why It Matters

Synlogic's drastic reduction in R&D and G&A expenses, coupled with a workforce reduction to a single employee, signals a company in deep strategic transition, potentially towards a merger or sale. For investors, this indicates a high-risk, speculative play, as the company's future hinges entirely on the success of its strategic alternatives review. Employees, beyond the one remaining, have already faced significant impact. Customers and the broader market for Synthetic Biotics will see a halt in Synlogic's direct contributions, potentially opening avenues for competitors or signaling challenges in the broader biopharmaceutical space for similar platforms. The competitive landscape will likely see other biopharmaceutical companies either acquire Synlogic's assets or fill the void left by its reduced operations.

Risk Assessment

Risk Level: high — The company has an accumulated deficit of $444.2 million as of September 30, 2025, and has historically generated negative cash flows from operations. Following a corporate restructuring in February 2024, the workforce was reduced to one full-time employee, and R&D expenses plummeted from $9.164 million to $16 thousand for the nine months ended September 30, 2025, indicating a near-complete cessation of core business activities. The company is actively evaluating strategic alternatives, including a potential merger or sale, which introduces significant uncertainty.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the company's minimal operational activity and reliance on a strategic alternative, potential investors should wait for concrete details regarding any merger or sale before considering a position. Existing shareholders should monitor developments closely for any announcements that could impact valuation.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$2.301M

eps

N/A

gross Margin

N/A

cash Position

$15.591M

revenue Growth

-100.0%

Revenue Breakdown

Key Numbers

• $2.301M — Net Loss (Q3 2025) (Increased significantly from $0.117M in Q3 2024)
• $2.513M — Net Loss (9M 2025) (Substantial improvement from $22.645M in 9M 2024)
• $0 — Revenue (Q3 & 9M 2025) (No revenue generated, down from $8K in 9M 2024)
• $16K — R&D Expenses (9M 2025) (Drastic reduction from $9.164M in 9M 2024)
• $2.454M — G&A Expenses (9M 2025) (Decreased from $5.228M in 9M 2024)
• $15.591M — Cash & Cash Equivalents (Sep 30, 2025) (Sufficient for 12 months of operations at current levels)
• $444.164M — Accumulated Deficit (Sep 30, 2025) (Indicates significant historical losses)
• 1 — Full-time Employee (Remaining after February 2024 corporate restructuring)
• $1.485M — Change in fair value of purchase warrant liability (Q3 2025) (Expense, contrasting with $376K income in Q3 2024)

Key Players & Entities

• SYNLOGIC, INC. (company) — Registrant and biopharmaceutical company
• SEC (regulator) — Securities and Exchange Commission
• $2.301 million (dollar_amount) — Net loss for Q3 2025
• $0.117 million (dollar_amount) — Net loss for Q3 2024
• $2.513 million (dollar_amount) — Net loss for nine months ended Sep 30, 2025
• $22.645 million (dollar_amount) — Net loss for nine months ended Sep 30, 2024
• $15.591 million (dollar_amount) — Cash and cash equivalents as of Sep 30, 2025
• $444.2 million (dollar_amount) — Accumulated deficit as of Sep 30, 2025
• February 2024 (date) — Date of corporate restructuring and workforce reduction
• one (person) — Remaining full-time employee after restructuring

FAQ

Risk Factors

• Drastic Reduction in Workforce and Operations [high — operational]: Following a corporate restructuring in February 2024, the company's workforce was reduced to one full-time employee. This led to a significant decrease in Research and Development expenses to $8 thousand for Q3 2025 and $16 thousand for the nine months ended September 30, 2025, down from $713 thousand and $9.164 million in the prior year, respectively. This extreme reduction in operational capacity raises concerns about future product development and market competitiveness.
• Increasing Net Loss and Negative Equity [high — financial]: The company reported a net loss of $2.301 million for Q3 2025, a significant increase from $0.117 million in Q3 2024. The accumulated deficit stands at $444.164 million as of September 30, 2025, indicating substantial historical unprofitability. While management states current cash of $15.591 million is sufficient for 12 months, the trend of increasing losses and zero revenue is concerning.
• Volatility in Fair Value of Purchase Warrant Liability [medium — financial]: A significant change in the fair value of purchase warrant liability resulted in an expense of $1.485 million for Q3 2025, contrasting sharply with a $376 thousand income in the prior year. This volatility can significantly impact reported net income and earnings per share, making financial performance less predictable.
• Lack of Revenue Generation [high — market]: The company has generated zero revenue for both the three and nine months ended September 30, 2025. This complete absence of sales, down from $8 thousand in the prior year's nine-month period, indicates a severe lack of market traction or a cessation of commercial activities.

Industry Context

Synlogic operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is highly competitive, with many companies vying for funding and market share. Recent trends include a focus on novel therapeutic modalities and personalized medicine, requiring substantial investment and innovation.

Regulatory Implications

As a biotechnology company, Synlogic is subject to stringent regulatory oversight from bodies like the FDA. Any changes in regulatory pathways or requirements for drug development and approval could significantly impact its operations and future prospects. Compliance with evolving healthcare regulations is critical.

What Investors Should Do

1. Monitor future R&D spending and any signs of renewed operational activity.
2. Scrutinize the source and sustainability of future funding.
3. Analyze the drivers behind the change in fair value of purchase warrant liability.

Key Dates

• 2024-02-01: Corporate Restructuring — Led to a reduction in workforce to one employee and a drastic cut in operating expenses, particularly R&D.
• 2025-09-30: End of Q3 2025 — Reported net loss of $2.301M, zero revenue, and cash of $15.591M.

Glossary

Accumulated Deficit

The total net losses of a company over its lifetime that have not been offset by net income. (Indicates Synlogic has historically incurred significant losses, with a deficit of $444.164 million as of September 30, 2025.)

Purchase Warrant Liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. When issued as part of a financing, it may be accounted for as a liability. (A significant expense of $1.485 million was recognized in Q3 2025 due to changes in its fair value, impacting net loss.)

Year-Over-Year Comparison

Compared to the prior year, Synlogic has seen a dramatic shift. Revenue has effectively ceased, dropping to $0 from $8 thousand in the nine-month period. While operating expenses, particularly R&D and G&A, have been slashed due to restructuring, leading to a much smaller net loss for the nine months ($2.513M vs. $22.645M), the Q3 net loss has widened significantly ($2.301M vs. $0.117M). A new risk factor has emerged with a substantial expense related to the fair value of purchase warrant liability.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SYBX The Nasdaq Capital M

Filing Documents

• sybx-20250930.htm (10-Q) — 1809KB
• sybx-ex31_1.htm (EX-31.1) — 15KB
• sybx-ex31_2.htm (EX-31.2) — 15KB
• sybx-ex32.htm (EX-32) — 7KB
• 0001193125-25-280270.txt ( ) — 7205KB
• sybx-20250930.xsd (EX-101.SCH) — 1144KB
• sybx-20250930_htm.xml (XML) — 1152KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained herein are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our evaluation of strategic alternatives with a goal to enhance stockholder value, including the possibility of a merger or a sale of the Company; the success of our research and development efforts; the initiation, progress, timing, costs and results of clinical trials for our product candidates; the time and costs involved in obtaining regulatory approvals for our product candidates; the success of our collaborations with third parties; the progress, timing and costs involved in developing manufacturing processes and in manufacturing products, as well as agreements with third-party manufacturers; the rate of progress and cost of our commercialization activities; the expenses we incur in marketing and selling our product candidates, if approved; the revenue generated by sales of our product candidates, if approved; the emergence of competing or complementary technological developments; the terms and timing of any additional collaborative, licensing or other arrangements that we may establish; the acquisition of businesses, products and technologies; our need to implement additional infrastructure and internal systems; our need to add personnel and financial and management info

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Unaudited Consolidated Balance Sheets 1 Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss) 2 Unaudited Consolidated Statements of Stockholders' Equity 3 Unaudited Consolidated Statements of Cash Flows 4 Notes to Unaudited Consolidated Financial Statements 5

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 13

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 23

Risk Factors

Item 1A. Risk Factors 23

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 24

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 24

Other Information

Item 5. Other Information 24

Exhibits

Item 6. Exhibits 25

Signatures

Signatures 26 SYNlogic, Inc. and SUBSIDIARIES Unaudited Consolida ted Balance Sheets (In thousands, except share amounts) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 15,591 $ 18,860 Prepaid expenses and other current assets 914 830 Assets held for sale — 86 Total current assets 16,505 19,776 Restricted cash 50 50 Total assets $ 16,555 $ 19,826 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 107 $ 164 Accrued expenses 858 2,037 Purchase warrant liability 5,265 4,874 Total current liabilities 6,230 7,075 Commitments and contingencies (Note 11) Stockholders' equity Common stock, $ 0.001 par value 250,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 11,978,711 shares issued and 11,698,919 shares outstanding as of September 30, 2025 and 11,975,901 shares issued and 11,696,109 shares outstanding as of December 31, 2024 12 12 Additional paid-in capital 456,995 456,908 Accumulated other comprehensive income — — Accumulated deficit ( 444,164 ) ( 441,651 ) Treasury stock, at cost ( 279,792 shares at September 30, 2025 and at December 31, 2024) ( 2,518 ) ( 2,518 ) Total stockholders' equity 10,325 12,751 Total liabilities and stockholders' equity $ 16,555 $ 19,826 The accompanying notes are an integral part of the unaudited consolidated financial statements. 1 Synlogic, INC. aND SUBSIDIARIES Unaudited Consolidated S tatements of Operations and Comprehensive Income (Loss) (In thousands, except share and per share amounts) For the Three Months Ended For the Nine Months Ended September 30, 2025 September 30, 2024 September 30, 2025 September 30, 2024 Revenue $ — $ — $ — $ 8 Operating expenses: Research and development 8 ( 713 ) 16 9,164 General and administrative 818 1,16

View Full Filing

View this 10-Q filing on SEC EDGAR